Exact Mass: 379.1202
Exact Mass Matches: 379.1202
Found 79 metabolites which its exact mass value is equals to given mass value 379.1202,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Hyaluronan biosynthesis, precursor 1
(2R,3R,4S)-2-{[(2R,3R,4R,5S,6R)-2,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-4-yl]oxy}-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
This compound belongs to the family of N-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moeity in which the oxygen atom is replaced by an n-acyl group.
2H-1-Benzopyran-2-one, 7-[[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]oxy]-4-methyl-
N-[4,5-dihydroxy-6-(hydroxymethyl)-2-[(4-methyl-2-oxo-2H-chromen-7-yl)oxy]oxan-3-yl]acetamide
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
2-({6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulphanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
Cyclohexanecarboxamide, N-(2-((ethylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-
N-((2-Ethylsulfonylamino)-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide monohydrate sodium salt
2-deoxy-N-glycoloyl-9-O-lactoyl-2,3-didehydroneuraminic acid
2-deoxy-N-glycoloyl-9-O-lactoyl-2,3-didehydroneuraminic acid
Hymecromone, O-(2-Acetamido-2-deoxy-beta-D-glucopyranoside)
Hymecromone, O-(2-Acetamido-2-deoxy-beta-D-glucopyranoside)
Coumarins
Cys Gly Asn Ser
(2S)-2-[(2S)-2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}-3-carbamoylpropanamido]-3-hydroxypropanoic acid
Cys Gly Ser Asn
(2S)-2-[(2S)-2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}-3-hydroxypropanamido]-3-carbamoylpropanoic acid
Cys Asn Gly Ser
(2S)-2-{2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]acetamido}-3-hydroxypropanoic acid
Cys Asn Ser Gly
2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]acetic acid
Cys Ser Gly Asn
(2S)-2-{2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]acetamido}-3-carbamoylpropanoic acid
Cys Ser Asn Gly
2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]acetic acid
Gly Cys Asn Ser
(2S)-2-[(2S)-2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid
Gly Cys Ser Asn
(2S)-2-[(2S)-2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid
Gly Asn Cys Ser
(2S)-2-[(2R)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid
Gly Asn Ser Cys
(2R)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid
Gly Ser Cys Asn
(2S)-2-[(2R)-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid
Gly Ser Asn Cys
(2R)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoic acid
Asn Cys Gly Ser
(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]acetamido}-3-hydroxypropanoic acid
Asn Cys Ser Gly
2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]acetic acid
Asn Gly Cys Ser
(2S)-2-[(2R)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-sulfanylpropanamido]-3-hydroxypropanoic acid
Asn Gly Ser Cys
(2R)-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-hydroxypropanamido]-3-sulfanylpropanoic acid
Asn Ser Cys Gly
2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]acetic acid
Asn Ser Gly Cys
(2R)-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]acetamido}-3-sulfanylpropanoic acid
Ser Cys Gly Asn
(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]acetamido}-3-carbamoylpropanoic acid
Ser Cys Asn Gly
2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]acetic acid
Ser Gly Cys Asn
(2S)-2-[(2R)-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}-3-sulfanylpropanamido]-3-carbamoylpropanoic acid
Ser Gly Asn Cys
(2R)-2-[(2S)-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}-3-carbamoylpropanamido]-3-sulfanylpropanoic acid
Ser Asn Cys Gly
2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]acetic acid
Ser Asn Gly Cys
(2R)-2-{2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]acetamido}-3-sulfanylpropanoic acid
Chondroitin
(2R,3R,4S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Urea, N-(4-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(4-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]- (9CI)
4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside
4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-2-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-2-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-6-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-6-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
4-Methylumbelliferyl-N-acetyl-beta-D-galactosaminide hydrate
4-Methylumbelliferyl-N-acetyl-beta-D-galactosaminide hydrate
6-Oxo-2-phenyl-5-[[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidineacetic acid
6-Oxo-2-phenyl-5-[[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidineacetic acid
(1-methylpiperidin-4-yl) 2-chloro-2,2-diphenylacetate,hydrochloride
(1-methylpiperidin-4-yl) 2-chloro-2,2-diphenylacetate,hydrochloride
4,11-diamino-2-(3-methoxypropyl)-1H-Naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
4,11-diamino-2-(3-methoxypropyl)-1H-Naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid
(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid
(3-Chloro-5-trifluoroMethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl)-carbaMic acid tert-butyl ester
(3-Chloro-5-trifluoroMethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl)-carbaMic acid tert-butyl ester
4-Methylumbelliferyl 2-amino-2-deoxy-a-D-glucopyranoside
4-Methylumbelliferyl 2-amino-2-deoxy-a-D-glucopyranoside
5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
Fuzapladib
Fuzapladib
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2144 - Endothelial-Specific Integrin/Survival Signaling Inhibitor D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors C308 - Immunotherapeutic Agent > C574 - Immunosuppressant Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
3-[Isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid
3-[Isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc
An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
(2R,3R,4S)-2-[(2R,3R,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
(2R,3R,4S)-2-[(2R,3R,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N-(4-fluorophenyl)urea
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N-(4-fluorophenyl)urea
4-(2,5-dimethoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione
4-(2,5-dimethoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione
(5E)-3-[(2-fluorophenyl)methyl]-5-[[1-(4-fluorophenyl)pyrrol-2-yl]methylidene]imidazolidine-2,4-dione
(5E)-3-[(2-fluorophenyl)methyl]-5-[[1-(4-fluorophenyl)pyrrol-2-yl]methylidene]imidazolidine-2,4-dione
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide
N-(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-bis(aminium)
N-(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-bis(aminium)
3-(4-Deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose
3-(4-Deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose
N-acetyl-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-D-galactosamine
N-acetyl-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-D-galactosamine
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
3-(4-deoxy-beta-D-gluc-4-enosyluronic acid)-N-acetyl-D-glucosamine
3-(4-deoxy-beta-D-gluc-4-enosyluronic acid)-N-acetyl-D-glucosamine
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
3-{1-[3,6-dihydroxy-5-(methanesulfinylmethyl)-2,5-dihydropyrazin-2-yl]ethyl}-3-hydroxy-1-methylindol-2-one
3-{1-[3,6-dihydroxy-5-(methanesulfinylmethyl)-2,5-dihydropyrazin-2-yl]ethyl}-3-hydroxy-1-methylindol-2-one
3-hydroxy-4,5-dimethoxy-6-[2-(5-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
3-hydroxy-4,5-dimethoxy-6-[2-(5-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(4s,5r,6r)-6-{[(3r,4r,5r,6r)-2,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylic acid
(4s,5r,6r)-6-{[(3r,4r,5r,6r)-2,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylic acid
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
3-hydroxy-4,5-dimethoxy-6-[2-(4-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
3-hydroxy-4,5-dimethoxy-6-[2-(4-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
3-hydroxy-4,5-dimethoxy-6-[2-(3-methyl-4-oxopentyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
3-hydroxy-4,5-dimethoxy-6-[2-(3-methyl-4-oxopentyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
